ORMP News and Press, Oramed Pharmaceuticals Inc. From 05/03/22

Oramed Completes Patient Enrollment in Pivotal Phase 3 Oral Insulin Study ORA-D-013-1 PR Newswire ORMD-0801 positioned to potentially be the first FDA approved oral insulin for the treatment of diabetes Completed enrollment of 710 patients for the Phase...

Oramed is developing oral insulin in a phase 3 trial, data this year. Nobody has been able to deliver insulin orally in adequate quantity. This is a $15bn market, and there is very little competition. For further details see: Oramed And Oral Insulin: Can This Small Compa...

Oramed Granted NASH Patent in Europe PR Newswire NEW YORK , April 5, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today annou...

Oramed Appoints Yadin Rozov to its Board of Directors PR Newswire NEW YORK , April 4, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, to...

Oramed's Diabetes Market Survey Shows Strong Interest for ORMD-0801 Oral Insulin Candidate Among Physicians - 76 Percent of the Physicians Responded They "Definitely Would" or "Probably Would" Prescribe Oramed's Oral Insulin Candidate for Type 2 Diabetes Patients PR Newswire...

Oramed to Host Key Opinion Leader Webinar on Need for Oral Insulin in Type 2 Diabetes Wednesday, March 30, 2022, at 12:00 p.m. ET PR Newswire NEW YORK , March 22, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed...

Oramed Completes Patient Enrollment in Phase 2 Oral Insulin NASH Trial - Topline results expected H2 2022 - ORMD-0801 is the first oral insulin to be evaluated as a treatment for NASH - Currently no FDA approved therapy exists for NASH PR Newswire NEW YORK ...

Oramed to Present at Barclays Global Healthcare Conference PR Newswire NEW YORK , March 10, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral dru...

Oramed Issues Annual Message to Shareholders - Oral insulin program continues to advance with topline efficacy data expected in H2 2022 - Significant value creation opportunities through oral COVID-19 vaccine program and partnerships - Well positioned to capitalize on op...

Oramed Granted Key European Patent for Platform Technology in Oral Delivery of Proteins - Protease inhibitor is a key component of Oramed's PODTM technology that protects therapeutic proteins in the digestive system - Oramed has already been granted this patent in the United...